분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2010-06-25 11:27:54 , Hit : 2385
 Molecular discovery suggests new strategy to fight cancer drug resistance

Public release date: 20-Jun-2010
[ Print | E-mail |  Share ] [ Close Window ]

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute


Prototype drug blocks MCL-1 protein that helps tumors survive treatment

BOSTON—Scientists at Dana-Farber Cancer Institute have found a way to disable a common protein that often thwarts chemotherapy treatment of several major forms of cancer.

The researchers discovered, surprisingly, that they could exploit a small portion of this anti-death protein, called MCL-1, to make a molecular tool that specifically blocked MCL-1's "pro-survival" action, allowing standard cancer drugs to kill the tumor cells by apoptosis, or programmed cell death.

"We think this is a very important step toward developing an inhibitor of MCL-1, which is emerging as a critical survival factor in a broad range of human cancers, including leukemia, lymphoma, multiple myeloma, melanoma, and poor-prognosis breast cancer to name just a few," said Loren Walensky, MD, PhD, a pediatric oncologist and chemical biologist at Dana-Farber and Children's Hospital Boston.

He is the senior author of the report being published June 20 on the website of Nature Chemical Biology. The first author is Michelle Stewart, a graduate student in the Walensky lab.

The researchers showed in lab experiments that combining the MCL-1 inhibitor with a class of conventional agents that can be rendered ineffective by MCL-1 resensitized the cancer cells to the drugs. The MCL-blocking compound is now being advanced to testing in animal models.

MCL-1 belongs to the BCL-2 family, a yin-and-yang collection of proteins that control the process of apoptosis, which is designed to rid the body of unneeded cells during embryonic development or cells that have become damaged or cancerous. The "pro-death" BCL-2 members form a pathway that triggers cellular self-destruction, while "pro-survival" members – of which MCL-1 is one – establish blockades in the death pathway, often by binding to pro-death proteins and disabling them.

Cancer cells exploit the survival pathway by over-expressing anti-apoptotic proteins such as MCL-1, which makes chemotherapy drugs less effective. Developing drugs to specifically target survival proteins like MCL-1 has been challenging, but Walensky has been making progress on that front.

A small, coiled peptide unit called BH3, which is known as the "death domain," is a key interaction point between pro- and anti-apoptotic proteins. Walensky previously showed that an isolated BH3 coiled structure could be reinforced by chemical "staples" and targeted to the BH3-binding domains of BCL-2 survival proteins, causing the cancer cells in which they are overexpressed to self-destruct.

BH3 domains differ in subtle but important ways from one another, like a set of keys for different locks. Walensky said that molecular mimics of these domains are showing great promise in early clinical trials, yet most of these drugs block three or more BCL-2 family proteins, rather than homing in on one specific cancer-causing target. "An ideal pharmacologic toolbox would contain agents that target individual BCL-2 family proteins, subsets, and all members," explained Walensky, who is also an assistant professor of pediatrics at Harvard Medical School.

In the current research, Walensky and Stewart searched through BH3 domains in cells hoping to find one that could bind to MCL-1 – but no other protein – and serve as a specific inhibitor of this formidable cancer protein. After combing a collection of BH3 domains, it turned out the one they were looking for was right in front of their eyes – the BH3 domain of MCL-1 itself.

The helical BH3 domain of MCL-1 is located within a small "pocket" in the protein structure, and acts as a dock to enable binding of other proteins. It is by means of this docking unit that MCL-1 "traps" pro-death proteins and keeps them from triggering apoptosis in cancer cells. The scientists didn't expect to find that MCL-1's own BH3 domain could, when inserted into the pocket, inhibit its own pro-survival behavior.

"When we uncovered nature's solution to selective MCL-1 targeting, we were surprised by the ironic twist," said Stewart.

The Dana-Farber investigators were also able to analyze the three-dimensional structure of the key parts of the MCL-1 docking mechanism and discover why it binds so specifically to its target.

"Our data provide a blueprint for the development of novel therapeutics to reactive apoptosis in diseases driven by pathologic MCL-1-mediated cell survival and chemoresistance," they wrote.


###

Other authors of the report are Emiko Fire, PhD, and Amy Keating, PhD, of the Massachusetts Institute of Technology.

The research was supported by grants from the National Institutes of Health.

Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's Cancer Center and it provides pediatric care with Children's Hospital Boston as Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.








947   Merck’s Hepatitis C Drug Wins F.D.A. Approval  이성욱 2011/05/17 2290
946   Mice Get Human Livers  이성욱 2010/02/24 4444
945   Microbe gets toxic response  이성욱 2010/12/10 2471
944   microRNA Discovery Might Help ALS Patients  이성욱 2009/12/14 4787
943   MicroRNAs Prevent Cell Reprogramming  이성욱 2011/10/27 3643
942   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 1179
941   MicroRNA를 매개하여 C형 간염을 치료하는 인터페론  이성욱 2007/10/25 4724
940   Minimal Genome Created  이성욱 2016/03/26 965
939   miRNA로 암줄기세포를 통제한다  이성욱 2007/12/20 5130
938   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1727
937   miRNA를 이용한 암살상바이러스의 지향성(tropism) 강화  이성욱 2008/11/01 4729
936   miRNA를 침묵시켜 C형간염을 치료  이성욱 2009/12/07 4704
935   miRNA와 Ago2에 의한 혈구세포의 발달과정 규명  이성욱 2007/08/02 5893
934   miro RNA  정흥수 2003/09/01 3983
933   Missing Molecules Hold Promise of Therapy for Pancreatic Cancer: Lost microRNAs Put Brakes on Tumors  이성욱 2010/12/22 2272
932   MIT 선정 2015년 주목받은 Biomedicine 뉴스  이성욱 2016/02/03 1008
  Molecular discovery suggests new strategy to fight cancer drug resistance  이성욱 2010/06/25 2385
930   Molecular Mechanism Triggering Parkinson's Disease Identified - miRNA  이성욱 2010/08/02 2474
929   Molecular scalpel hope for Duchenne muscular dystrophyBy James Gallagher  이성욱 2011/07/28 2942
928   More support for RNAi in clinic  이성욱 2010/03/23 2907

[이전 10개] [1]..[11][12][13][14][15][16] 17 [18][19][20]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN